Royalty Pharma plc (RPRX) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
RPRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RPRX Revenue Analysis (2017–2025)
As of March 5, 2026, Royalty Pharma plc (RPRX) generated trailing twelve-month (TTM) revenue of $2.35 billion, reflecting solid growth of +7.9% year-over-year. The most recent quarter (Q3 2025) recorded $609.3 million in revenue, up 5.3% sequentially.
Looking at the longer-term picture, RPRX's 5-year compound annual growth rate (CAGR) stands at +2.3%, indicating moderate growth over time. The company achieved its highest annual revenue of $2.38 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows RPRX's business is primarily driven by Financial Royalty Assets (95%), and Royalty Income, Other (5%). With over half of revenue concentrated in Financial Royalty Assets, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LGND (+64.8% YoY), INVA (+14.5% YoY), and BTX, RPRX has underperformed the peer group in terms of revenue growth. Compare RPRX vs LGND →
Peer Comparison
Compare RPRX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RPRXCurrent | $2.3B | +7.9% | +2.3% | 65.6% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% | |
 INVA | $425M | +14.5% | +4.8% | 38.5% | |
 BTX | $41M | - | - | 87.7% | |
 XOMAP | $28M | +118.0% | +9.2% | -140.3% | |
 XOMA | $28M | +191.2% | +9.2% | -140.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.38B | +5.1% | $0 | - | $1.56B | 65.6% |
| 2024 | $2.26B | -3.9% | $2.26B | 100.0% | $1.29B | 57.1% |
| 2023 | $2.35B | +5.2% | $2.35B | 100.0% | $1.49B | 63.4% |
| 2022 | $2.24B | -2.3% | $2.24B | 100.0% | $307.1M | 13.7% |
| 2021 | $2.29B | +7.9% | $2.29B | 100.0% | $1.43B | 62.5% |
| 2020 | $2.12B | +17.0% | $1.89B | 89.1% | $1.60B | 75.2% |
| 2019 | $1.81B | +1.1% | $1.81B | 100.0% | $2.62B | 144.6% |
| 2018 | $1.79B | +12.3% | $1.79B | 100.0% | $1.36B | 76.0% |
| 2017 | $1.60B | - | $1.60B | 100.0% | $939.7M | 58.8% |
See RPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RPRX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RPRX vs AGIO
See how RPRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RPRX's revenue growth accelerating or slowing?
RPRX maintains +7.9% revenue growth, in line with its 5-year CAGR of +2.3%. TTM revenue stands at $2.3B. Growth rate remains consistent with historical average.
What is RPRX's long-term revenue growth rate?
Royalty Pharma plc's 5-year revenue CAGR of +2.3% reflects the sustained expansion pattern. Current YoY growth of +7.9% is near this long-term average.
How is RPRX's revenue distributed by segment?
RPRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.